(Q48503591)

12 February 2018

title

Burden of a multiple sclerosis relapse: the patient's perspective. (English)

1 reference

12 February 2018

main subject

multiple sclerosis

0 references

author name string

Merrikay Oleen-Burkey

1

1 reference

12 February 2018

Jane Castelli-Haley

2

1 reference

12 February 2018

Maureen J Lage

3

1 reference

12 February 2018

Kenneth P Johnson

4

1 reference

12 February 2018

publication date

1 January 2012

1 reference

12 February 2018

number of pages

13

1 reference

The Patient: Patient-Centered Outcomes Research

inferred from page(s)

published in

1 reference

12 February 2018

volume

5

1 reference

12 February 2018

issue

1

1 reference

12 February 2018

page(s)

57-69

1 reference

12 February 2018

https://scigraph.springernature.com/pub.10.2165/11592160-000000000-00000

exact match

0 references

cites work

The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

A comprehensive assessment of the cost of multiple sclerosis in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

Relapse management in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

The psychosocial effect of multiple sclerosis: the impact of relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

The costs and consequences of multiple sclerosis relapses: a managed care perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

A questionnaire to assess neurological impairment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

EQ-5D: a measure of health status from the EuroQol Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

Costs and quality of life of patients with multiple sclerosis in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

Multiple sclerosis in the UK: service use, costs, quality of life and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

The cost of multiple sclerosis in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

Cost of managing an episode of relapse in multiple sclerosis in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

Burden and health-related quality of life of Spanish caregivers of persons with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

Informal caregiving in multiple sclerosis patients: data from the Madrid Demyelinating Disease Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

Costs and quality of life of multiple sclerosis in the United Kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

The emotional and psychological impact of multiple sclerosis relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

Cost of multiple sclerosis by level of disability: a review of literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

Effect of relapses on development of residual deficit in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

Impact of multiple sclerosis relapses on progression diminishes with time

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592160-000000000-00000

Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population

21 January 2018

1 reference

12 December 2020

The validity and reproducibility of a work productivity and activity impairment instrument

1 reference

12 December 2020

Cost and health related quality of life consequences of multiple sclerosis

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis

1 reference

12 December 2020

Contribution of relapses to disability in multiple sclerosis

1 reference

12 December 2020

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

12 December 2020

The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics

1 reference

12 December 2020

Communities of Care and Caring: The Case of MSWatch.com(R)

1 reference

12 December 2020

Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database

1 reference

12 December 2020

A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy

1 reference

12 December 2020

Survey of multiple sclerosis in northern California. Northern California MS Study Group

1 reference

12 December 2020

A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium.

1 reference

12 December 2020

10.2165/11592160-000000000-00000

Identifiers

DOI

1 reference

12 February 2018

Dimensions Publication ID

0 references

1 reference

12 February 2018